Bivalirudin, a bivalent, thrombin specific anticoagulant as an alternative to heparin in interventional procedures

Hamostaseologie

Volumn 22, Issue 3, 2002, Pages 142-148

  Chew, Derek P ^a  

^a FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

Anticoagulant; Bivalirudin; Percutaneous coronary intervention; Thrombia inhibitor; Unstable angina

Indexed keywords

ABCIXIMAB; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; STREPTOKINASE;

ACUTE HEART INFARCTION; ANTICOAGULATION; BLEEDING; CLINICAL TRIAL; DOSE RESPONSE; DRUG MECHANISM; HUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PHARMACODYNAMICS; REVIEW;

EID: 0036375302     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1619549     Document Type: Review

References (25)

1. Design and characterization of hirulogs: A novel class of bivalent peptide inhibitors of thrombin
2. Direct thrombin inhibitors for treatment of arterial thrombosis: Potential differences between bivalirudin and hirudin
3. The thrombin-specific anticoagulant, bivalirudin, completely inhibits thrombin-mediated platelet aggregation
4. Anticoagulant activity of Hirulog, a direct thrombin inhibitor, in humans
5. Hirulog: A direct thrombin inhibitor for management of acute coronary syndromes
6. Anticoagulant effects of hirulog, a novel thrombin inhibitor, in patients with coronary artery disease
7. Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty
8. Bivalirudin for percutaneous coronary interventions: Development perspective
9. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or post infarction angina. Hirulog Angioplasty Study Investigators
10. Bivalirudin versus heparin during coronary angioplasty for unstable or post-infarction angina: The final reanalysis of the bivalirudin angioplasty study
11. Dosage, pharmacological effects and clinical outcomes for bivalirudin in percutaneous coronary intervention
12. Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention
13. Heparin variability and resistance: Comparison with a direct thrombin inhibitor
14. Pre-clinical and clinical studies on Hirulog: A potent and specific direct thrombin inhibitor
15. Usefulness and tolerability of hirulog, a direct thrombin-inhibitor, in unstable angina pectoris
16. Initial experience with a direct antithrombin, Hirulog, in unstable angina. Anticoagulant, antithrombotic, and clinical effects
17. Hirulog in the treatment of unstable angina. Results of the Thrombin Inhibition in Myocardial Ischemia (TIMI) 7 trial
18. A second look at bivalirudin
19. Bivalirudin as a replacement for unfractionated heparin in unstable angina/non-ST-elevation myocardial infarction: Observations from the TIMI 8 trial
20. A pilot, early angiographic patency study using a direct thrombin inhibitor as adjunctive therapy to streptokinase in acute myocardial infarction
21. Randomized double-blind comparison of two doses of Hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction
22. Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Hirulog Early Reperfusion/Occlusion (HERO) Trial Investigators
23. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: The HERO-2 randomized trial
24. Direct thrombin inhibitors in acute coronary syndromes: Principal results of a meta-analysis based on individual patient data